Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
Ramez N Eskander, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA Abstract: Despite advances in cytotoxic chemotherapy and surgical cytoreduction, disease recurrence continues to be a troubling problem in patien...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-10-01
|
| Series: | Clinical Pharmacology: Advances and Applications |
| Online Access: | http://www.dovepress.com/epithelial-cell-adhesion-molecule-directed-trifunctional-antibody-immu-a14572 |
| _version_ | 1818937298371215360 |
|---|---|
| author | Eskander RN Tewari KS |
| author_facet | Eskander RN Tewari KS |
| author_sort | Eskander RN |
| collection | DOAJ |
| description | Ramez N Eskander, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA Abstract: Despite advances in cytotoxic chemotherapy and surgical cytoreduction, disease recurrence continues to be a troubling problem in patients with advanced-stage epithelial ovarian cancer (EOC). Malignant ascites affects approximately 10% of patients with recurrent EOC and is associated with troublesome symptoms, including abdominal pressure, distension, dyspnea, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced-stage ovarian cancer. Recently, immune modulation has gained attention as a novel approach to anti-cancer therapy. This review explores the role of epithelial cell-adhesion molecule (EpCAM)-directed immunotherapy, with a specific focus on the mechanism of action of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3). In addition, clinical trials exploring the use of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer are reviewed. Keywords: ovarian cancer, immunotherapy, catumaxomab, CD3, EpCAM |
| first_indexed | 2024-12-20T05:49:44Z |
| format | Article |
| id | doaj.art-45c2c02ff8e54951b639934194324e47 |
| institution | Directory Open Access Journal |
| issn | 1179-1438 |
| language | English |
| last_indexed | 2024-12-20T05:49:44Z |
| publishDate | 2013-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Pharmacology: Advances and Applications |
| spelling | doaj.art-45c2c02ff8e54951b639934194324e472022-12-21T19:51:13ZengDove Medical PressClinical Pharmacology: Advances and Applications1179-14382013-10-012013Supplement 15561Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancerEskander RNTewari KSRamez N Eskander, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA Abstract: Despite advances in cytotoxic chemotherapy and surgical cytoreduction, disease recurrence continues to be a troubling problem in patients with advanced-stage epithelial ovarian cancer (EOC). Malignant ascites affects approximately 10% of patients with recurrent EOC and is associated with troublesome symptoms, including abdominal pressure, distension, dyspnea, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced-stage ovarian cancer. Recently, immune modulation has gained attention as a novel approach to anti-cancer therapy. This review explores the role of epithelial cell-adhesion molecule (EpCAM)-directed immunotherapy, with a specific focus on the mechanism of action of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3). In addition, clinical trials exploring the use of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer are reviewed. Keywords: ovarian cancer, immunotherapy, catumaxomab, CD3, EpCAMhttp://www.dovepress.com/epithelial-cell-adhesion-molecule-directed-trifunctional-antibody-immu-a14572 |
| spellingShingle | Eskander RN Tewari KS Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer Clinical Pharmacology: Advances and Applications |
| title | Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer |
| title_full | Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer |
| title_fullStr | Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer |
| title_full_unstemmed | Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer |
| title_short | Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer |
| title_sort | epithelial cell adhesion molecule directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer |
| url | http://www.dovepress.com/epithelial-cell-adhesion-molecule-directed-trifunctional-antibody-immu-a14572 |
| work_keys_str_mv | AT eskanderrn epithelialcelladhesionmoleculedirectedtrifunctionalantibodyimmunotherapyforsymptommanagementofadvancedovariancancer AT tewariks epithelialcelladhesionmoleculedirectedtrifunctionalantibodyimmunotherapyforsymptommanagementofadvancedovariancancer |